|
Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). |
|
|
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Novartis; Roche |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis |
Patents, Royalties, Other Intellectual Property - University Hospital Essen |
|
|
No Relationships to Disclose |
|
Filip Yves Francine Leon De Vos |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
Honoraria - Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
Honoraria - Array BioPharma; Genentech; Merck |
Consulting or Advisory Role - Array BioPharma; Genentech; Merck |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Roche |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Roche |
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Almirall; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Almirall; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD; Novartis; Pierre Fabre; Roche |
Research Funding - Johnson & Johnson (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche |
Research Funding - Federal Ministry of Education and Research |
Expert Testimony - Novartis; Roche |
|
|
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Oncosec |
Honoraria - EMD Serono; Inovio Pharmaceuticals |
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec |
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy |
|
|
Employment - Array BioPharma |
Stock and Other Ownership Interests - Array BioPharma |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis |
|
|
Employment - Array BioPharma; Takeda |
Stock and Other Ownership Interests - Array BioPharma; Takeda |
Patents, Royalties, Other Intellectual Property - Takeda |
|
|
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst) |